IDEAYA Enrolls First Patient in IDE892 Phase 1 Trial with ~1,400-Fold Selectivity
IDEAYA Biosciences enrolled first patient in Phase 1 trial of IDE892, a PRMT5 inhibitor with ~1,400-fold selectivity and single-digit nanomolar potency in MTAP-deleted solid tumors. IDEAYA plans IDE892 combination with MAT2A inhibitor IDE397 in mid 2026 and will nominate a CDKN2A-deficiency candidate in H2 2026 with IND in H1 2027.
1. Phase 1 Trial Enrollment
IDEAYA enrolled the first patient in its Phase 1 IDE892 trial targeting MTAP-deleted solid tumors, including non-small cell lung and pancreatic cancers. The open-label study will assess safety, tolerability, pharmacokinetics and pharmacodynamics of IDE892 as monotherapy and later in combination.
2. IDE892 Preclinical Profile
IDE892 demonstrated ~1,400-fold selectivity for MTA-PRMT5 over SAM-PRMT5 complexes and single-digit nanomolar potency in MTAP-deleted cell lines. Preclinical monotherapy studies showed tumor regressions, while combination with IDE397 yielded durable complete responses at well-tolerated doses.
3. IDE397 Combination Plan
A combination trial of IDE892 with IDE397, IDEAYA’s MAT2A inhibitor, is slated for mid 2026 to exploit synthetic lethal vulnerabilities from dual PRMT5 and MAT2A inhibition in MTAP-deleted tumors. The company expects this regimen to maximize clinical efficacy with manageable safety.
4. CDKN2A-Deficiency Program and Pipeline Prioritization
IDEAYA aims to nominate a first-in-class CDKN2A-deficiency development candidate in H2 2026 and file an IND in H1 2027, addressing a lesion present in over 80% of pancreatic cancers. To focus resources, clinical combinations with Trodelvy have been deprioritized in favor of proprietary MTAP-deletion and CDKN2A assets.